Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis

Dan Li1,2,3†, Fan Fei4†, Hua Yu2, Xiangning Huang2, Shanshan Long2, Hao Zhou5* and Jie Zhang2*

1School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, 2Department of Laboratory Medicine, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China, 3Department of Laboratory Medicine, Medical Center Hospital of Qionglai City, Chengdu, China, 4Department of Neurosurgery, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China, 5Department of Stomatology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China

Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.

Methods: PubMed, Embase, Web of Science, CNKI, and Wanfang Data databases were searched from their inception up to March 31, 2021, to obtain studies on ceftazidime-avibactam therapy versus ceftazidime-avibactam-based combination therapy in patients with carbapenem-resistant Gram-negative pathogens. The primary outcome was mortality rate, and the second outcomes were microbiologically negative, clinical success, and the development of resistance after ceftazidime-avibactam treatment.

Results: Seventeen studies representing 1,435 patients (837 received ceftazidime-avibactam-based combination therapy and 598 received ceftazidime-avibactam therapy) were included in the meta-analysis. The results of the meta-analysis showed that no statistically significant difference was found on mortality rate (Petos odds ratio (OR) = 1.03, 95% confidence interval (CI) 0.79–1.34), microbiologically negative (OR = 0.99, 95% CI 0.54–1.81), and clinical success (OR = 0.95, 95% CI 0.64–1.39) between ceftazidime-avibactam-based combination therapy and ceftazidime-avibactam therapy. Although there was no difference in posttreatment resistance of ceftazidime-avibactam (OR = 0.65, 95% CI 0.34–1.26) in all included studies, a trend favoring the combination therapy was found (according to the pooled three studies, OR = 0.18, 95% CI 0.04–0.78).

Conclusions: The current evidence suggests that ceftazidime-avibactam-based combination therapy may not have beneficial effects on mortality, microbiologically negative, and clinical success to patients with carbapenem-resistant Gram-negative pathogens. A trend of posttreatment resistance occurred more likely in ceftazidime-
avibactam therapy than the combination therapy. Due to the limited number of studies that can be included, additional high-quality studies are needed to verify the above conclusions.

**Keywords:** ceftazidime-avibactam therapy, combination therapy, carbapenem-resistant gram-negative pathogen, efficacy, meta-analysis

**INTRODUCTION**

Infections caused by carbapenem-resistant Gram-negative bacilli (CRGN) are challenging and associated with a high mortality rate (CDC, 2019); it spreads rapidly in the past decade causing a huge public health burden (Bassetti et al., 2017; Avendano et al., 2020; Zhen et al., 2021). Until now, several antimicrobial agents have been developed to fight against these superbugs, among which, ceftazidime-avibactam (CAZ-AVI) is a novel antibiotic combination, consisting of a third-generation cephalosporin (ceftazidime) and a synthetic β-lactamase inhibitor (avibactam). The special chemical structure allows avibactam to bond closely to and inactivate class A, class C, and some class D β-lactamases, but not class B metallo-β-lactamas (Zhan et al., 2013).

Previous *in vitro* studies (Gaibani et al., 2017; Romanelli et al., 2020) demonstrated that the CAZ-AVI activity was enhanced after combining other agents. However, the results of combination therapy are inconclusive in real-world experiences (Tumbarello et al., 2015; Sousa et al., 2018). Additionally, phase 3 randomized clinical programs have assessed the efficacy of CAZ-AVI compared with other therapies (Carmeli et al., 2016; Wagenlehner et al., 2016) but not with CAZ-AVI-based combination therapy. In 2015, CAZ-AVI was first approved for marketing by the US Food and Drug Administration (FDA) for the treatment of adults (age >18) with serious infections including complicated intra-abdominal infection (cIAI) (along with metronidazole) and complicated urinary tract infection (cUTI) (Administration FSDa, 2015). This scenario occurred only when there were limited or no other therapeutic options. Subsequently, it was approved by the European Medicines Agency (EMA) in 2016 (Shirley, 2018), by the National Medical Products Administration in China in 2019 (14) and in other countries (15, 16). A wealth of CAZ-AVI treating CRGN studies in real-world practice has been reported. There has been a dispute on whether monotherapy would be inferior to combination therapy (15). Also, this debate occurred in the posttreatment CAZ-AVI scenario (Shields et al., 2018; Tumbarello et al., 2019; Ackley et al., 2020; Castón et al., 2020; Iannaccone et al., 2020; Tumbarello et al., 2021).

Therefore, a meta-analysis aiming to systematically compare the mortality rate, microbiologically negative, clinical success, and the development of resistance between CAZ-AVI therapy and CAZ-AVI-based combination therapy was conducted.

**METHODS**

**Reporting Guideline**
The meta-analysis was reported according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines (Page et al., 2021). The PRISMA checklist was provided as Supplementary Material.

**Database Search**

Multiple databases, including PubMed, Embase, Web of Science, CNKI, and Wanfang Data, were searched for the studies on CAZ-AVI therapy and CAZ-AVI-based combination therapy for the treatment of infections caused by CRGN (up to March 31, 2021). The search keywords were “ceftazidime avibactam” and “carbapenem resistant. The search strategy was provided as Supplementary Material. The references of relevant articles (both original research and reviews) were also inspected. The search article and reference inspection were performed by two researchers independently screening the titles and abstracts and examining the full texts and reference lists according to the inclusion and exclusion criteria listed below and (Bassetti et al., 2017) cross-checking each other’s studies.

**Inclusion criteria:**

i) All types of clinical studies were included: both randomized controlled trials (RCTs) and observational studies (retrospective and prospective).

ii) Studies with availability separate data on CAZ-AVI therapy and any CAZ-AVI-based combination therapy.

iii) Studies reported more than ten adult patients (age >18) with infections caused by CRGN.

iv) No language restrictions on the articles: eligible studies published in any languages were all included.

**Exclusion criteria:**

i) *In vitro* studies, reviews, or case reports (n < 10).

ii) Data on CAZ-AVI therapy or CAZ-AVI-based combination regimen were not reported.

In case of insufficient data provided in the eligible articles, corresponding authors were contacted for more information.

**Data Extraction**
The primary outcome was the mortality rate at an appropriate time point (14, 30, and 90 days, in hospital), and the secondary outcomes were microbiologically negative, clinical success, and the development of resistance after CAZ-AVI treatments. Two researchers independently extracted and cross-checked the studies to ensure the selected studies were unique based on the following information of the studies: the first author, published year, country, study design, patient demographics (age, sex, and number of patients), bacteria, carbapenemase, the severity of illness, comorbidity index, combination agents, and infection type.

**Quality Assessment and Definitions**
The Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I) tool (Sterne et al., 2016a) was used to evaluate the risk of bias in observational studies (11 cohort studies and 1 case-cohort study). The tool includes seven bias domains: confounding
domain, domain of selection of participants, classification domain, deviations domain, missing data, measurement domain, and domain of selection of the reported result. The risk of bias for individual studies was assessed by two researchers answering signal questions according to a hypothetical randomized trial. According to the design of the study, the Agency for Healthcare Research and Quality (AHRQ) tool (Rostom et al., 2004) was applied to evaluate the residual five studies (two case series and three cross-sectional studies). Each study was assessed independently by two researchers, and if there was a dispute, a third researcher was employed to resolve the dispute.

The definitions were based on studies included in this meta-analysis. Combination therapy was defined as one or more agents combined with CAZ-AVI for at least 24 h of treatment. Clinical success was defined as the resolution or remarkable improvement of the symptoms and signs of infection caused by CRGN. Microbiologically negative was defined as negative culture from blood or specific sites at the end of the treatment. CRGN was defined as resistance to any carbapenem using an automated or manual methodology.

**Statistical Analysis**

RevMan 5.3 software was used to perform the meta-analysis. Pooled odds ratios (ORs) or Peto ORs and 95% confidence intervals (CIs) were computed in the analysis. $I^2$ and Q statistics were used to evaluate the heterogeneity. $I^2 > 50\%$ and $p < 0.1$ are assumed as clinical heterogeneity. A fixed-effects model was performed for the meta-analysis. Subgroup analyses were performed according to the endpoint of mortality. Sensitivity analyses were performed as well. $p$-value less than 0.05 was considered significant.

**RESULTS**

**Study Search and Characteristics**

The database search described in Database Search generated 17 eligible articles (Sousa et al., 2018; Kuang et al., 2020; Guimarães et al., 2019; Rathish et al., 2021; Shields et al., 2018; Tumbarello et al., 2019; Ackley et al., 2020; Iannaccone et al., 2020; Castón et al., 2020; Tumbarello et al., 2021; Zhu et al., 2021; King et al., 2017; Temkin et al., 2017; De la Calle et al., 2019; Chen et al., 2020;
Jiang et al., 2020; Jorgensen et al., 2020). Specifically, 1,106 references were found by searching for the keywords: “ceftazidime avibactam” and “carbapenem resistant.” After removing the duplicates, 667 potentially relevant articles were left. The 620 records containing only titles and abstracts were then excluded. The remaining 47 studies were further screened using the inclusion and exclusion criteria and returned 17 articles. The details of the database search flow are shown in the study selection flowchart (Figure 1). We used the PRISMA2020 tool (R package and ShinyApp for making PRISMA2020 flow diagrams) (Haddaway et al., 2021) to generate the flow diagram (Figure 1).

The basic information of the 17 articles included in the meta-analysis was summarized (Table 1). There are 11 cohort studies, one case-cohort study, two case series, and three case-sectional studies and all of them were retrospective observational. In total, 1,435 patients were included in this analysis, and the number of patients for different studies ranged from 10 (Chen et al., 2020) to 577 (Tumbarello et al., 2021). The studies were published between 2017 and 2021. Four studies were from the USA (King et al., 2017; Shields et al., 2018; Ackley et al., 2020; Jorgensen et al., 2020), three were from Spain (Sousa et al., 2018; De la Calle et al., 2019; Castón et al., 2020), four were from China (Chen et al., 2020; Jiang et al., 2020; Kong et al., 2020; Zhu et al., 2021), three were from Italy (Tumbarello et al., 2019; Iannaccone et al., 2020; Tumbarello et al., 2021), one was from Brazil (Guimarães et al., 2019), one was from India (Rathish et al., 2021), and one was from Europe and Australia (Temkin et al., 2017). In terms of the pathogens, most of the studies reported carbapenem-resistant Enterobacteriaceae (CRE) with carbapenem-resistant Klebsiella pneumoniae (CKP) as the most frequent, while one study included both CKP and carbapenem-resistant Pseudomonas aeruginosa (CRPA) (Temkin et al., 2017) and one study reported CRE, CRPA, and Acinetobacter baumannii (AB) (Kuang et al., 2020). As for infection types, most studies demonstrated more than one type of infection, while two were only bloodstream infections (BSI) (Tumbarello et al., 2019; Iannaccone et al., 2020), and one was pneumonia (Jiang et al., 2020). Reagents that have been combined with CAZ-AVI therapy include aminoglycosides (AMG), polymyxin (PM), ticagrelide (TGC), colistin (COL), amikacin (AMK), imipenem (IMP), gentamicin (GEN), ciprofloxacin (CIP), meropenem (MEM), fosfomycin (FOS), carbapenems (CAP), fluoroquinolone (FLU), minocycline (MIN), and sulfamethoxazole-trimethoprim (SUL-TRI).

Patients were treated by CAZ-AVI and observed for at least 72 h in 12 studies (Temkin et al., 2017; Shields et al., 2018; De la Calle et al., 2019; Tumbarello et al., 2019; Iannaccone et al., 2020; Jorgensen et al., 2020; Castón et al., 2020; Chen et al., 2020; Jiang et al., 2020; Kong et al., 2020; Zhu et al., 2021), for at least 48 h in three studies (Sousa et al., 2018; Guimarães et al., 2019; Rathish et al., 2021), and for at least 24 h in one study (King et al., 2017). There is only one study in which the treatment time was not reported (Iannaccone et al., 2020).

Robvis tool (McGuinness and Higgins, 2021) was applied for the publication quality (risk-of-bias) assessment. The risk-of-bias assessment results for each study (Figure 2A) and each domain (Figure 2B) are displayed. Ten studies (King et al., 2017; Shields et al., 2018; De la Calle et al., 2019; Tumbarello et al., 2019; Ackley et al., 2020; Castón et al., 2020; Chen et al., 2020; Jorgensen et al., 2020; Kuang et al., 2020; Rathish et al., 2021) have a critical overall risk of bias (judged by one study was at critical risk of bias in at least one domain (Sterne et al., 2016b)) and two moderates (Sousa et al., 2018; Tumbarello et al., 2021). The quality of the other five studies assessed by the AHRQ tool is all poor quality (Table 2).

**Meta-Analysis**

**Mortality**

Out of the 17 included eligible studies, three studies (Shields et al., 2018; Jiang et al., 2020; Zhu et al., 2021) did not extract separate data on mortality rates from CAZ-AVI therapy alone or in combination with other drugs. Given the fact that most studies’ overall risk of bias was critical, a subgroup meta-analysis was not performed based on the risk-of-bias levels but on mortality at an appropriate time point (14, 30, and 90 days, in hospital). Sensitivity analyses were performed according to the study design, comorbidity index, illness severity, bacteria, infection type, and carbapenemase. There was no statistically significant difference in the overall mortality rates between CAZ-AVI therapy alone and ceftazidime-avibactam-based combination therapy (Peto OR = 1.03, 95% CI 0.79–1.34; I² = 0%) (Figure 3).

For the 14-day mortality, the Peto OR was 0.90 (95% CI 0.32–2.50; I² = 45%) with no significant difference, but there were only three articles (Sousa et al., 2018; Kuang et al., 2020; Guimarães et al., 2019) and 106 patients included. Moderate clinical heterogeneity (I² = 45%; p = 0.16) was observed for one report (Kuang et al., 2020), which may be due to the pathogen complexity (including CRE, CRPA, and AB). By excluding this study, I² was 0%, and the Peto OR was 0.50 (95% CI 0.15–1.64).

Six studies (Sousa et al., 2018; Kuang et al., 2020; Tumbarello et al., 2019; Castón et al., 2020; Tumbarello et al., 2021; Jorgensen et al., 2020) were used to assess the 30-day mortality rate, contributing to 63.0% of the weight. No significant heterogeneity existed among these studies (I² = 0%; p = 0.93), and there was no statistically significant difference between CAZ-AVI therapy and combination therapy (Peto OR = 0.96, 95% CI 0.69–1.33; I² = 0%). The Peto OR of 90-day mortality assessment was 1.74 (95% CI 0.79–3.82; I² = 0%), thus exhibiting no significant difference. Three studies (De la Calle et al., 2019; Ackley et al., 2020; Chen et al., 2020) consisting of 139 patients were included in this analysis. For the in-hospital mortality assessment, four studies (King et al., 2017; Temkin et al., 2017; Iannaccone et al., 2020; Rathish et al., 2021) were included with Peto OR = 1.01 (95% CI 0.55–1.86; I² = 0%).

**Clinical Success**

Ten studies (King et al., 2017; Temkin et al., 2017; Shields et al., 2018; Sousa et al., 2018; De la Calle et al., 2019; Ackley et al., 2020; Jiang et al., 2020; Kuang et al., 2020; Rathish et al., 2021; Zhu et al., 2021) were included in the clinical success analysis, in which only one (case series) study (Temkin et al., 2017) did not define clinical success, and the other nine studies defined clinical success as resolution or remarkable improvement of the symptoms and different signs of infection at some point (such as the endpoint)
| Study | Combination therapy drug | Country | Combination therapy design | Study design | No. of patients | Sex, male [n (%)] | Age median (IQR) | Bacteria | Carbapenemase | CCI [median (IQR)] | The severity of illness [median (IQR)] | Infection type |
|-------|--------------------------|---------|----------------------------|--------------|-----------------|----------------|----------------|----------|-------------|---------------------|-------------------|---------------|
| King et al. (2017) | AMG, PM, and TGC | USA | Ret | 60 | 36 (60) | 51–69 | CPE | NR | 4.5 (3–7) | 2 (0–5) | Mix |
| Temkin et al. (2017) | ERP, AMG, PM, TGC, and MEM | Europe and Australia | CS | 38 | 25 (85.8) | 47–67 | CPE and CRPA | KPC and OXA-48 | NR | NR | Mix |
| Sousa et al. (2018) | COL, TGC, AMK, and CAP | Spain | Ret | 57 | 44 (77) | 64 (range, 24–86) | CPE | OXA-48 | 3 (0–13) | 24 (8–45) | Mix |
| De la Calle et al. (2019) | AMK, TGC, and COL | Spain | Ret | 24 | 19 (82.6) | 58.85 (SD = 16.03) | CPE and E. coli | OXA-48 | 4.3 (SD = 2.9) | 3.3 (SD = 2.8) | Mix |
| Shields et al. (2018) | GEN, COL, TGC, AMK, and CIP | USA | Ret | 77 | 47 (61) | 62 (range, 19–91) | CPE | KPC-2 and KPC-3 | 4 (range, 0–10) | 5 (range, 0–20) | Mix |
| Guimarães et al. (2019) | TGC, PM, MEM, AMK, GEN, and FOS | Brazil | Ret | 29 | 18 (62) | 50.5 (SD = 5) | CPE | KPC-2 | 2 (range, 0–5) | 2 (range, 0–16) | Mix |
| Tumbarello et al. (2019) | GEN, TGC, COL, FOS, and CAP | Italy | CC | 104 | 68 (65.4) | 61 (27–79) | CKP | KPC | ≥3 (36.5%) | 4 (0–7) | BSI |
| Iannaccone et al. (2020) | TGC, COL, GEN, FOS, and MEM | Italy | Cs | 23 | 21 (91) | 57 (range, 18–80) | CKP | KPC | NR | NR | BSI |
| Jorgensen et al. (2020) | AMG, TGC, and PM | USA | Ret | 109 | 58 (53) | 63 (53–74) | CRE | NR | 4 (2–7) | 5 (9–8) | Mix |
| Castón et al. (2020) | GEN, TGC, COL, and FOS | Spain | Ret | 47 | 29 (81.7) | 70 (54–79) | CKP | KPC | 4 (2–4) | 3 (2–6) | Mix |
| Jiang et al. (2020) | CAP, AMK, TGC, and PM | China | Cs | 41 | 34 (82.9) | 62.4 (SD = 15.2) | CKP | NR | NR | NR | NR | Pneumonia |
| Chen et al. (2020) | TGC and PM | China | Ret | 10 | 10 (100) | 51 (range, 31–68) | CKP and FOS | KPC-2 | NR | 5.8 (range, 1–13) | Mix |
| Ackley et al. (2020) | CAP, AMG, PM, COL, TGC, FLU, and SUL-TRI | USA | Ret | 105 | 58 (55.2) | 62 (51–69) | CRE and CRPA | Partial KPC | 5 (3–6) | 26 (22–30) | Mix |
| Kuang et al. (2020) | TGC, PM, AMK, FOS, and MEM | China | Ret | 20 | 14 (70) | 54.5 (SD = 17.37) | CRE, AB, and CRPA | NR | 4.2 (SD = 4.63) | Mix |
| Tumbarello et al. (2021) | FOS, TGC, GEN, MEM, COL, and AMK | Italy | Ret | 57 | 386 (66.9) | 66 (56–76) | CKP | KPC | CCI ≥ 3 (94.7%) | ≥8 (31.2%) | Mix |
| Zhu et al. (2021) | CAP, TGC, PM, and FLU | China | Cs | 11 | 7 (63.6) | 55 (range, 39–69) | CKP | NR | NR | NR | Mix |
| Rathish et al. (2021) | TGC, PM, MEM, MIN, and FLU | India | Ret | 103 | 81 (79) | 53.2 (SD = 17.9) | CRE | NR | 4.1 (SD = 2.3) | 4.3 (SD = 3.2) | Mix |

**ABB:** Acinetobacter baumannii; **AMG:** aminoglycosides; **AMK:** amikacin; **BSI:** bloodstream infection; **CAP:** carbapenem; **CC:** case cohort; **CCI:** Charlson Comorbidity Index; **CIP:** ciprofloxacin; **CRPA:** carbapenem-resistant Klebsiella Pneumonia; **COL:** colistin; **CRE:** carbapenemase-producing Enterobacteriaceae; **CPE:** carbapenem-resistant Enterobacteriaceae; **CRPA:** carbapenem-resistant Pseudomonas aeruginosa; **CS:** case series; **CS:** case sectional; **ERP:** ertapenem; **FLU:** fluoroquinolone; **FOS:** fosfomycin; **GEN:** gentamicin; **IMP:** imipenem; **IQR:** interquartile range; **MEM:** meropenem; **MIN:** minocycline; **NR:** not report; **PM:** polymyxin; **Ret:** retrospective cohort; **SD:** standard deviation; **SOFA:** Sequential Organ Failure Assessment; **SUL-TRI:** sulfamethoxazole-trimethoprim; **TGC:** tigecycline.

*In-hospital mortality.

Minimum therapy time > 24 h.

Minimum therapy time > 72 h.

Minimum therapy time > 14 days.

Minimum therapy time > 30 days.

Minimum therapy time > 48 h.

APACHE II score.

SOFA score.

Not report minimum therapy time.
(Sousa et al., 2018; De la Calle et al., 2019; Ackley et al., 2020), absence of recurrent infections (Shields et al., 2018; De la Calle et al., 2019; Ackley et al., 2020), or resistance to CAZ-AVI (Rathish et al., 2021). Sensitivity analyses were performed according to the study design, definitions of clinical success, illness severity, and carbapenemase. However, no statistical difference was observed based on a pooled OR of 0.95 (95% CI 0.64–1.39; I² = 0%) (Figure 4).

Microbiologically Negative
Five studies (King et al., 2017; Temkin et al., 2017; Sousa et al., 2018; Castón et al., 2020; Chen et al., 2020) reported the outcomes of microbiologically negative, including a total of 212 patients. Out of these studies, three studies defined the microbiologically negative as sterilization of the index culture at the end of treatment or an appropriate point (7 days) (King et al., 2017; Sousa et al., 2018; Castón et al., 2020), while the other two studies had no definitions (Temkin et al., 2017; Chen et al., 2020). Sensitivity analyses were performed according to the study design, definitions of microbiologically negative, illness severity, and carbapenemase, and there was no significant difference. The pooled OR of the five studies was 0.99 (95% CI 0.54–1.81; I² = 0%) (Figure 5).

Posttreatment Resistance of CAZ-AVI
Six studies (Shields et al., 2018; Tumbarello et al., 2019; Ackley et al., 2020; Iannaccone et al., 2020; Castón et al., 2020; Tumbarello et al., 2021) assessed the development of resistance after CAZ-AVI treatment, in which 967 patients (642 in CAZ-AVI-based combination therapy and 325 in CAZ-AVI therapy) were included. Sensitivity analyses were performed by the study design, the illness severity, comorbidity index, and infection type. Heterogeneity was either low or absent, and no difference was observed (Figure 6). Klebsiella pneumoniae carbapenemase-(KPC-) producing isolates were reported in all the six studies, with
one study (Shields et al., 2018) reporting both KPC-2 and KPC-3 and another study (Ackley et al., 2020) reporting parts of the isolates as KPC-producing bacteria. In our analysis, there was no significant difference (OR = 0.65, 95% CI 0.34–1.26; \( I^2 = 0\% \)). However, when we pooled only three studies (Tumbarello et al., 2019; Ackley et al., 2020; Iannaccone et al., 2020) including 266 participants, the pooled OR was 0.18 (95% CI 0.04–0.78; \( I^2 = 0\% \)) favoring CAZ-AVI-based combination therapy. Therefore, we observed a posttreatment resistance trend in CAZ-AVI alone therapy (Figure 6, \( p\)-value = 0.2). Further study with larger samples would need to be conducted to confirm this assumption.

**DISCUSSION**

The mortality, clinical success, microbiologically negative, and posttreatment resistance between CAZ-AVI therapy alone and in combination with other agents were compared. The results indicate that CAZ-AVI concomitant therapy may not exhibit beneficial effects on mortality, clinical success, and microbiologically negative to patients infected with CRGN. This is consistent with the two previous meta-analyses (one reported only mortality (Fiore et al., 2020), and the other one reported mortality and microbiologically negative (Onorato et al., 2019)). However, a trend of posttreatment resistance is likely to occur in the CAZ-AVI therapy based on the pooled three studies, OR = 0.18, 95% CI 0.04–0.78).

Four subgroups were analyzed on data regarding mortality, and the discrepancies were not significant, which is consistent with previous studies reported by Fiore (Fiore et al., 2020) and Onorato (Onorato et al., 2019). Gutiérrez-Gutiérrez et al. (Gutiérrez-Gutiérrez et al., 2017) reported no difference observed in overall mortality rates between patients who received antibiotics concurrent with other agents (colistin plus tigecycline most common) and monotherapy (any but not CAZ-AVI) treating carbapenemase-producing Enterobacteriaceae (CPE) infections. However, in the high-mortality-score patients, combination therapy was related to lower mortality compared with monotherapy. Another study conducted by Tumbarello (Tumbarello et al., 2015) demonstrated that combination therapy including meropenem improved survival rates in severity illness patients with KPC-Kp infections. Here, we performed sensitivity analyses according to the severity of illness, and no significant difference was observed.

Clinical success, which was first evaluated in our meta-analysis, showed no difference in the 10 studies (Sousa et al., 2018; Kuang et al., 2020; Rathish et al., 2021; Shields et al., 2018; Ackley et al., 2020; Zhu et al., 2021; King et al., 2017; Temkin et al., 2017; De la Calle et al., 2019; Jiang et al., 2020) included (OR = 0.95, 95% CI 0.64–1.39; \( I^2 = 0\% \)). Results of microbiologically negative were evaluated in five studies (Sousa et al., 2018; Castón et al., 2020; King et al., 2017; Temkin et al., 2017; Chen et al., 2020) and showed no discrepancies (OR = 0.99, 95% CI 0.54–1.81; \( I^2 = 0\% \)). Out of the five studies, two studies (Temkin et al., 2017; Chen et al., 2020) did not define the microbiologically negative. Besides, to the best of our knowledge, this was the first meta-analysis to systematically evaluate the development of resistance after CAZ-AVI treatment alone or in combination with other agents. CAZ-AVI was first approved by the US FDA (Tumbarello et al., 2015) in 2015, and subsequently, rapidly
emerging resistance was first reported by Humphries et al. (Humphries et al., 2015). In their study, an old woman with infections caused by KPC-producing KP (KPC-3) received salvage therapy and developed resistance to CAZ-AVI after 9 days of treatment (Humphries et al., 2015). In our meta-analysis, six studies (Shields et al., 2018; Tumbarello et al., 2019; Ackley et al., 2020; Iannaccone et al., 2020; Castón et al., 2020; Tumbarello et al., 2021) reported posttreatment resistance of CAZ-AVI, and only one study (Shields et al., 2018) provided detailed information on the potential mechanism of CAZ-AVI resistance that both KPC-2- and KPC-3-producing CRE were included (Shields et al., 2018). Interestingly, resistance emerged only from KPC-3-producing isolates. This is consistent with the study reported by Humphries et al. (Humphries et al., 2015). Further study is needed to unravel the potential resistance mechanism of CAZ-AVI posttreatment. Additionally, although there was no significant difference (OR = 0.65, 95% CI 0.34–1.26; \( I^2 = 0\% \)) in CAZ-AVI resistance between treatment in combination and alone, combination therapy was more likely associated with lower resistance when we pooled three studies (Tumbarello et al., 2019; Ackley et al., 2020; Iannaccone et al., 2020) (OR = 0.18, 95% CI 0.04–0.78; \( I^2 = 0\% \)). Further studies with a larger sample size are needed to test this assumption. Given that CAZ-AVI concomitant with other antibiotics (such as TGC or COL) may result in potential side effects or toxicity (Sousa et al., 2018), decisions regarding CAZ-AVI-based combination therapy should be made according to the traits of patients.

This study has several limitations. Firstly, all studies included were retrospective observational design studies, with no RCTs or prospective observational studies included. Secondly, the overall risk of bias of most studies was critical. Thirdly, the sample sizes of several subgroups were small. Fourth, due to the fact that the data on the type of infection between CAZ-AVI therapy alone or
in combination with other agents were not available, subgroup analysis was not performed according to the infection type.

In summary, studies for CAZ-AVI single therapy or CAZ-AVI combination therapy in patients with CRGN infections were analyzed. The outcomes including mortality, clinical success, microbiologically negative, and posttreatment resistance were compared, and no significant differences were observed between the two therapies. To the best of the authors’ knowledge, this is the first meta-analysis study accessing the resistance between CAZ-AVI treatment alone and in combination. However, given the low quality of the evidence and limited samples in some subgroups, definitive conclusions
cannot be made. RCTs and large prospective observational studies are needed to evaluate these issues in future studies.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS

JZ and HZ designed the study. JZ and SL contributed to manuscript writing and revised and supervised the project. DL and FP contributed to literature searches. HY and XH checked the data. All authors approved the manuscript.

FUNDING

This work was supported by the National Natural Science Foundation of China (81702064).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.707499/full#supplementary-material

REFERENCES

Ackley, R., Rosdy, D., Meredith, J., Minor, S., Anderson, W. E., Capraro, G. A., et al. (2020). Meropenem–vaborbactam Versus Ceftazidime–Avibactam for Treatment of Carbapenem–Resistant Enterobacteriaceae Infections. Antimicrob. Agents Chemother. 64 (5), e02313. doi:10.1128/aac.02313-19

Administration USFaD (2015). Drug Trials Snapshot: AVYCAZ (cIAI). Available at: https://wwwfdagov/drugs-drug-approvals-and-databases/drug-trials-snapshot-avycaz-ciai. Accessed July 31, 2021.

Avendano, E. E., Raman, G., Chan, J., and McCann, E. (2020). Burden of Carbapenem Non-susceptible Infections in High-Risk Patients: Systematic Literature Review and Meta-Analysis. Antimicrob. Resist. Infect. Control. 9 (1), 193. doi:10.1186/s13756-020-00858-8

Bassetti, M., Poulakou, G., Ruppe, E., Bouza, E., Van Hal, S. J., and Brink, A. (2017). Antimicrobial Resistance in the Next 30 years. Humankind, Bugs and Drugs: A Visionary Approach. Intensive Care Med. 43 (10), 1464–1475. doi:10.1007/s00134-017-4878-x

Carmeli, Y., Armstrong, J., Laud, P. J., Newell, P., Stone, G., Wardman, A., et al. (2016). Ceftazidime–avibactam or Best Available Therapy in Patients with Ceftazidime–Resistant Enterobacteriaceae and Pseudomonas aeruginosa Complicated Urinary Tract Infections or Complicated Intra-abdominal Infections (REPRISE): A Randomised, Pathogen-Directed, Phase 3 Study. Lancet Infect. Dis. 16 (6), 661–673. doi:10.1016/s1473-3099(16)30004-4

Castón, J. J., Gallo, M., García, M., Cano, A., Escobano, A., Machuca, I., et al. (2020). Ceftazidime-avibactam in the Treatment of Infections Caused by KPC-Producing Klebsiella pneumoniae: Factors Associated with Clinical Efficacy in a Single-center Cohort. Int. J. Antimicrob. Agents. 56 (3), 106075. doi:10.1016/j.ijantimicag.2020.106075

CDC (2019). Antibiotic Resistance Threats in the United States 2019. Available at: https://www.cdc.gov/drugresistance/pdf/reports/2019-ar-threats-report-508pdf. Accessed April 15, 2021.

Chen, W., Sun, L., Guo, L., Cao, B., Liu, Y., Zhao, L., et al. (2020). Clinical Outcomes of Ceftazidime-Avibactam in Lung Transplant Recipients with Infections Caused by Extensively Drug-Resistant Gram-Negative Bacilli. Ann. Transl. Med. 8 (3), 39. doi:10.21037/atm.2019.10.40

De la Calle, C., Rodríguez, O., Morata, L., Marco, F., Cardozo, C., García-Vidal, C., et al. (2019). Clinical Characteristics and Prognosis of Infections Caused by OXA-48 Carbapenemase-Producing Enterobacteriaceae in Patients Treated with Ceftazidime-Avibactam. Int. J. Antimicrob. Agents. 53 (4), 520–524. doi:10.1016/j.ijantimicag.2018.11.015

Fiore, M., Alfieri, A., Di Franco, S., Pace, M. C., Simeon, V., Ingoglia, G., et al. (2020). Ceftazidime-avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis. Antibiotics (Basel) 9 (7), 388. doi:10.3390/antibiotics9070388

Gaibani, P., Lewis, R. E., Volpe, S. L., Giannella, M., Campoli, C., Landini, M. P., et al. (2017). In Vitro Interaction of Ceftazidime-Avibactam in Combination with Different Antimicrobials Against KPC-Producing Klebsiella pneumoniae Clinical Isolates. Int. J. Infect. Dis. 65, 1–3. doi:10.1016/j.ijid.2017.09.017

Guimarães, T., Noué, S. A., Martins, R. C. R., Pêrdugo Neto, L. V., Martins, W. M. B. S., Narciso Barbosa, A. C., et al. (2019). Ceftazidime-avibactam as Salvage Therapy for Infections Caused by Enterobacteriaceae Corresistent to Carbapenems and Polymyxins. Antimicrob. Agents Chemother. 63 (10), e00528. doi:10.1128/aac.00528-19

Gutiérrez-Gutiérrez, B., Salamanca, E., de Cueto, M., Hseuh, P. R., Viale, P., Pardo, J. R., et al. (2017). Effect of Appropriate Combination Therapy on Mortality of Patients with Bloodstream Infections Due to Carbapenemase-Producing Enterobacteriaceae (INCREMENT): A Retrospective Cohort Study. Lancet Infect. Dis. 17 (7), 726–734. doi:10.1016/s1473-3099(17)30228-1

Haddaway, N. R., Page, M. J., Pritchard, C. C., and McGuinness, L. A. (2021). PRISMA2020: R Package and Shiny App for Producing PRISMA 2020 Compliant Flow diagrams/(Version 0.2). Zenodo.

Humphries, R. M., Yang, S., Hemarajata, P., Ward, K. W., Hindler, J. A., Miller, S. A., et al. (2015). First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate. Antimicrob. Agents Chemother. 59 (10), 6605–6607. doi:10.1128/aac.01165-15

Innacone, M., Boattini, M., Bianco, G., Corcione, S., Cavallo, R., and Costa, C. (2020). Ceftazidime-avibactam Susceptible to Resistant KPC-Producing Enterobacteriaceae Bloodstream Infections: An Observational Study. J. Chemother. 32 (3), 160–162. doi:10.1080/1120009x.2019.1709363

Jiang, T., Deng, F., and Yun, B. (2020). Efficacy of Ceftazidime-Avibactam Therapy in Patients with Pneumonia Infections Caused by Carbapenem-Resistant Klebsiella Pneumoniae. Jiangsu Med. J. 46 (12), 1286–1288. doi:10.19460/j.cnki.0253-3685.2020.12.025

Jorgensen, S. C. J., Trinh, T. D., Zasowski, E. J., Lagnf, A. M., Bhatia, S., Melvin, S. M., et al. (2020). Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPII Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime-Avibactam. Infect. Dis. Ther. 9 (2), 291–304. doi:10.1007/s40121-020-00288-4

King, M., Heil, E., Kuriakose, S., Bias, T., Huang, V., El-Beyrouty, C., et al. (2017). Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections. Antimicrob. Agents Chemother. 61 (7), e00449. doi:10.1128/aac.00449-17

Kuang, H., Zhong, C., Wang, Y., Ye, H., Ao, K., Zong, Z., et al. (2020). Clinical Characteristics and Outcomes of Patients with Multidrug-Resistant Gram-Negative Bacterial Infections Treated with Ceftazidime/avibactam. J. Glob. Antimicrob. Resist. 23, 404–407. doi:10.1016/j.jgar.2020.10.023

McGuinness, L. A., and Higgins, J. P. T. (2021). Risk-of-bias V5Sualization (Rolvis): An R Package and Shiny Web App for Visualizing Risk-Of-Bias Assessments. Res. Synth. Methods 12 (1), 55–61. doi:10.1002/jrs.1411

Onorato, L., Di Caprio, G., Signorillo, S., and Coppola, N. (2019). Efficacy of Ceftazidime/avibactam in Monotherapy or Combination Therapy Against
